Please use this identifier to cite or link to this item:
Title: Prevalence of CYP2C19 and CYP3A4 in poor metabolizers among inhabitants of Tlaxcala, Mexico
Author: Gonzalez, H.M.
Gomez-Martinez, L.E.
Chavez, C., T.D.J.
Trevino, R.
Romero, E.M.
Hoyo-Vadillo, C.
Issue Date: 2006
Abstract: We recently described the presence of the P450 isozymes, CYP2C19 and CYP3A4 among ultra-extensive metabolizers in a Mexican Population from Jalisco state. We found 6% and 11% of poor metabolizers of CYP2C19 and CYP3A4, respectively. As different regions of Mexico differ in the genetic admixture, we now report results from subjects of Tlaxcala state, which has a higher Amerindian population than the state of Jalisco. Thirteen healthy volunteers participated in the study. They received 20 mg of omeprazole (Losec, AstraZeneca) orally. The study had the approval of the Ethics Committee of the Hospital Regional #14 del IMSS in Guadalajara, Mexico. Omeprazole and its metabolites were determined 3 hours after drug administration. A validated HPLC method was employed. The metabolic indexes were measured as omeprazole/hydroxyomeprazol and omeprazol/omeprazole sulphone for 2C19 and 3A4 respectively. No ultra-extensive metabolizers were detected. Poor metabolizers were 31% for 2C19 and 45% for 3A4. These values are much higher than those described in other populations (Fisher exact test: p=0.015 and p<0.001, respectively). These results are surprising for the Tlaxcala group, and could be a result of the sample size, and the differences in genetic admixture of this population. Our findings suggest that a larger study may be warranted to further validate population genotyping.
Appears in Collections:Producción científica UdeG

Files in This Item:
There are no files associated with this item.

Items in RIUdeG are protected by copyright, with all rights reserved, unless otherwise indicated.